"Dactinomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
| Descriptor ID |
D003609
|
| MeSH Number(s) |
D03.633.300.200 D04.345.566.252 D12.644.641.252
|
| Concept/Terms |
Cosmegen- Cosmegen
- Cosmegen Lyovac
- Lyovac, Cosmegen
- Lyovac-Cosmegen
- Lyovac Cosmegen
- LyovacCosmegen
|
Below are MeSH descriptors whose meaning is more general than "Dactinomycin".
Below are MeSH descriptors whose meaning is more specific than "Dactinomycin".
This graph shows the total number of publications written about "Dactinomycin" by people in this website by year, and whether "Dactinomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dactinomycin" by people in Profiles.
-
Kube P, Parisio K, Mangum DS, Powell J. Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity. BMJ Case Rep. 2022 Aug 29; 15(8).
-
Ashton E, Szutowska M, Shafer A, Hoffman J. Attempted conservative management of a placental site trophoblastic tumor: a case report. Conn Med. 2014 Sep; 78(8):475-7.
-
Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, Fought AJ, Bentrem DJ, Talamonti MS, Bell RH, Adrian TE. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007 Apr; 138(2):163-9.
-
Kubota S, Hatanaka M, Pomerantz RJ. Nucleo-cytoplasmic redistribution of the HTLV-I Rex protein: alterations by coexpression of the HTLV-I p21x protein. Virology. 1996 Jun 15; 220(2):502-7.
-
Dodge GR, Kovalszky I, Hassell JR, Iozzo RV. Transforming growth factor beta alters the expression of heparan sulfate proteoglycan in human colon carcinoma cells. J Biol Chem. 1990 Oct 15; 265(29):18023-9.
-
Kuo BS, Dryjski M, Bjornsson TD. Influence of nicotine and cotinine on the expression of plasminogen activator activity in bovine aortic endothelial cells. Thromb Haemost. 1989 Feb 28; 61(1):70-6.
-
Kuo BS, Korner G, Dryjski M, Bjornsson TD. Role of polyamines in the stimulation of synthesis and secretion of plasminogen activator from bovine aortic endothelial cells. J Cell Physiol. 1988 Oct; 137(1):192-8.
-
Kuo BS, Korner G, Bjornsson TD. Effects of sulfonylureas on the synthesis and secretion of plasminogen activator from bovine aortic endothelial cells. J Clin Invest. 1988 Mar; 81(3):730-7.
-
Gasic GJ, Gasic TB, Jimenez SA. Platelet aggregating material in mouse tumor cells. Removal and regeneration. Lab Invest. 1977 Apr; 36(4):413-9.
-
Herzog J, Farber JL. Inhibition of rat liver RNA polymerases by action of the methylating agents dimethylnitrosamine in vivo and methyl methanesulfonate in vitro. Cancer Res. 1976 May; 36(5):1761-70.